trial

4 coronavirusc

AstraZeneca announces ‘robust’ results from anti-COVID drug trial

This transmission electron microscope image shows SARS-CoV-2 — also known as 2019-nCoV, the virus that causes COVID-19 — isolated from a patient in the US. Virus particles are shown emerging from the surface of cells cultured in the lab. The spikes on the outer edge of the virus particles give coronaviruses their name, crown-like. Credit: …

AstraZeneca announces ‘robust’ results from anti-COVID drug trial Read More »

Trial compares two devices used for percutaneous left atrial appendage closure

Trial compares two devices used for percutaneous left atrial appendage closure

Credit: Unsplash/CC0 Public Domain SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure (LAAC) as evaluated by 45-day cardiac computed tomography angiography (CCTA). The study showed that the two devices achieve a similar rate of …

Trial compares two devices used for percutaneous left atrial appendage closure Read More »

Using fluvoxamine to treat COVID-19 patients reduces the need for prolonged hospitalization, trial shows

Using fluvoxamine to treat COVID-19 patients reduces the need for prolonged hospitalization, trial shows

The results of a new randomized clinical trial, published in The Lancet Global Health, have demonstrated that using fluvoxamine to treat high-risk outpatients with early-diagnosed COVID-19 reduced the need for prolonged observation in an emergency setting or hospitalization, compared to a control group who received a placebo. This arm of the TOGETHER trial is the …

Using fluvoxamine to treat COVID-19 patients reduces the need for prolonged hospitalization, trial shows Read More »

Study: SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial. Image Credit: Adao/ Shutterstock

Phase 1 open-label trial shows SARS-CoV-2 DNA vaccine induces durable immune response

The currently available coronavirus disease 2019 (COVID-19) vaccines have markedly reduced the burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) where available. Still, the global disparity in availability and concerns regarding the emergence of vaccine-evading mutants continue to encourage vaccine development. Study: SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted …

Phase 1 open-label trial shows SARS-CoV-2 DNA vaccine induces durable immune response Read More »

New trial shows vaginal laser therapy treatments may not work at all

New trial shows vaginal laser therapy treatments may not work at all

This laser is supposed to rejuvenate vaginal tissue. But scientists say it’s no better than a placebo You might want to think twice before forking out for an expensive vaginal laser therapy treatment, scientists say. Photo: Shutterstock. Vaginal laser therapy treatments claim to reduce negative vaginal symptoms of menopause – experienced by about half of …

New trial shows vaginal laser therapy treatments may not work at all Read More »

'Elite neutralizing' antibody demonstrates long-term viral suppression in persons living with HIV in phase 1 trial

‘Elite neutralizing’ antibody demonstrates long-term viral suppression in persons living with HIV in phase 1 trial

Credit: Pixabay/CC0 Public Domain In the 40 years since the first published reports of the syndrome known as AIDS, more than 32 million people have died from the virus that causes it, the human immunodeficiency virus (HIV). With more than 35 million people worldwide living with HIV today and nearly two million new cases each …

‘Elite neutralizing’ antibody demonstrates long-term viral suppression in persons living with HIV in phase 1 trial Read More »

AstraZeneca logs upbeat trial results from COVID drug

AstraZeneca logs upbeat trial results from COVID drug

Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: NIAID British pharmaceuticals giant AstraZeneca on Monday revealed more positive results from a trial of a treatment for COVID-19 symptoms. The drug, made from a combination of two …

AstraZeneca logs upbeat trial results from COVID drug Read More »

New technology leads successful clinical trial to treat dry eye disease

New technology leads successful clinical trial to treat dry eye disease

A team led by Hironmoy Das, Ph.D., from the TTUHSC Jerry H. Hodge School of Pharmacy recently completed a clinical trial using corneal epithelial stem cells to improve outcomes for DED patients. Credit: TTUHSC Several studies conducted over the last decade have concluded that dry eye disease (DED) affects up to 50% of the U.S. …

New technology leads successful clinical trial to treat dry eye disease Read More »

Pfizer launches mRNA flu vaccine trial

Pfizer launches mRNA flu vaccine trial

“The Covid-19 pandemic allowed us to deliver on the immense scientific opportunity of mRNA,” Kathrin Jansen, head of vaccine research at Pfizer, said in a statement. US pharmaceutical company Pfizer said Monday it had begun a clinical trial to test an influenza vaccine designed with the same mRNA technology behind its successful COVID-19 shot. The …

Pfizer launches mRNA flu vaccine trial Read More »

Pfizer starts large trial for anti-COVID pill

Pfizer starts large trial for anti-COVID pill

Credit: Pixabay/CC0 Public Domain Pfizer said Monday it had begun a middle-to-late stage clinical trial of a pill to stave off COVID in people who are exposed to infection. Several companies are working on so-called oral antivirals, which would mimic what the drug Tamiflu does for influenza and prevent the disease from progressing to severe. …

Pfizer starts large trial for anti-COVID pill Read More »